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Abstract
Background: Recovery from cytomegalovirus meningoencephalitis with brain stem death in an immunocompetent
patient is almost impossible. We present a remarkable recovery from a possible cytomegalovirus infection in an
immunocompetent man who had severe neurological syndromes, suggesting brain stem death complicated by
pneumonia and pleural effusion.
Case presentation: A 19-year-old Asian man presented at our hospital’s emergency department with reduced
consciousness and seizures following high fever, headache, confusion, and vomitus within a week before arrival.
He was intubated and sent to our intensive care unit. He had nuchal rigidity and tetraparesis with accentuated
tendon reflexes. Electroencephalography findings suggested an acute structural lesion at his right temporal area
or an epileptic state. A cerebral spinal fluid examination suggested viral infection. A computed tomography scan
was normal at the early stage of disease. Immunoglobulin M, immunoglobulin G anti-herpes simplex virus, and
immunoglobulin M anti-cytomegalovirus were negative. However, immunoglobulin G anti-cytomegalovirus was
positive, which supported a diagnosis of cytomegalovirus meningoencephalitis. His clinical condition deteriorated,
spontaneous respiration disappeared, cranial reflexes became negative, and brain stem death was suspected.
Therapy included antivirals, corticosteroids, antibiotics, anticonvulsant, antipyretics, antifungal agents, and a
vasopressor to maintain hemodynamic stability. After 1 month, he showed a vague response to painful stimuli
at his supraorbital nerve and respiration started to appear the following week. After pneumonia and pleural effusion
were resolved, he was weaned from the ventilator and moved from the intensive care unit on day 90.
Conclusions: This case highlights several important issues that should be considered. First, the diagnosis of brain
stem death must be confirmed with caution even if there are negative results of brain stem death test for a long
period. Second, cytomegalovirus meningoencephalitis should be considered in the differential diagnosis even for
an immunocompetent adult. Third, accurate therapy and simultaneous intensive care have very important roles in
the recovery process of patients with cytomegalovirus meningoencephalitis.
Keywords: Meningoencephalitis, Cytomegalovirus, Brain stem death, Immunocompetent
Abbreviations: BSD, Brain stem death; CMV, Cytomegalovirus; CRP, C-reactive protein; CT, Computed tomography;
EEG, Electroencephalography; ICU, Intensive care unit; Ig, Immunoglobulin
* Correspondence: theresiarahardjo@gmail.com
1Anesthesiology Department, Faculty of Medicine, Maranatha Christian
University, Bandung, Indonesia
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rahardjo et al. Journal of Medical Case Reports  (2016) 10:238 
DOI 10.1186/s13256-016-1034-0
Background
Cytomegalovirus (CMV) causes severe diseases in im-
munocompromised patients, leading to significant mor-
bidity and mortality, either through viral reactivation
from latent CMV infection or primary CMV infection.
Encephalitis, pneumonitis, hepatitis, uveitis, retinitis,
colitis, and graft rejection are some of the clinical syn-
dromes that can be observed in such patients. However,
little attention has been paid to CMV infection in im-
munocompetent patients [1, 2]. CMV infection in im-
munocompetent patients is usually asymptomatic because
cell-mediated host immune responses prevent the devel-
opment of overt CMV disease. However, some severe
clinical manifestations of CMV infection in several condi-
tions of immunocompetent patients have been reported.
Critically ill patients, severity of illness markers, mechan-
ical ventilation, bacterial pneumonia, sepsis, and transfu-
sion may be associated with CMV infection risk [3]. Of
interest, the seroprevalence of CMV is 20 to 30 % higher
in non-white populations worldwide, suggesting that
Asian people have a higher risk of CMV infection [4].
The most severe manifestation of CMV infection in
immunocompetent patients is meningoencephalitis, which
is characterized by seizures and coma as clinical manifes-
tations. Ventriculoencephalitis is a CMV infection with
brain stem involvement characterized by severe cranial
nerves dysfunction and can lead to brain stem death
(BSD) [5, 6]. Lung involvement can manifest as pneumo-
nia or interstitial pneumonitis [7]. There is no existing
data on the recovery process in immunocompetent pa-
tients with CMV meningoencephalitis with BSD. Some
studies have only focused on CMV manifestation in im-
munocompromised patients. A few notable cases of CMV
diseases manifested as kidney, gastrointestinal tract, and
liver abnormalities, but no brain stem involvement was
observed [8]. A case of CMV meningitis was previously
reported, but was not accompanied by encephalitis, BSD
or pneumonia with pleural effusion as complicating
factors [9]. We present an exceptional case of an immuno-
competent patient who recovered from BSD caused by
CMV meningoencephalitis.
Case presentation
A 19-year-old Asian man presented at our hospital’s
emergency department with reduced consciousness and
seizures. He had a Glasgow Coma Score of 11 to 12, and
was agitated and confused during the first 2 days. He ex-
perienced two to three general tonic–clonic seizures of
approximately 15 to 30 seconds’ duration each within
hours of each other, and he was awake between seizures.
His seizures started with stiffness in his whole body and
his eyes were rolled back during seizures. His Glasgow
Coma Score was reduced to 8 on the third day and he
was intubated and sent to our intensive care unit (ICU).
He had a continuous high fever, ranging from 39 °C to
40 °C, headache, confusion, and vomitus. His fever
began to decline to 38.0 °C several hours before hospital
admission. He and his family had no history of epilepsy,
weakness and paralysis of limbs, drug abuse, tobacco
smoking, or alcoholism.
A physical examination showed nuchal rigidity and
tetraparesis with accentuated tendon reflexes. Cranial
nerves and ophthalmoscopy examinations were nor-
mal. An immediate electroencephalography (EEG)
showed periodic epileptogenic waves at his right tem-
poral area and general bitemporal cortical dysfunction.
These findings suggested an acute structural lesion at
his right temporal area or an epileptic state, and a pos-
sible viral cause.
Evaluation of hematology showed dynamic changes of
leukocytes and C-reactive protein (CRP) level during his
illness. His white blood cell count and CRP reached peak
level at day 70 when ventilator-associated pneumonia
and pleural effusion occurred (Table 1). Coagulation pa-
rameters and a liver function test showed normal values.
A cerebral spinal fluid examination showed a white
blood cell count of 16/mm3, polymorphonucleocytes
(PMN) of 13/mm3, mononuclear (MN) cells of 87/mm3,
glucose level of 42/dL, and an increased protein level of
216 mg/dL, which suggested a nonspecific viral infec-
tion. Gram, India ink, and Ziehl–Neelsen stains were
negative. Computed tomography (CT) scans were per-
formed twice, on 2 September 2014 (day 6) and 22
September 2014 (day 26). The first CT scan result was
normal (Fig. 1 left) but the second showed a smeared
bright area in ependymal cells at the lower area of the
third ventricle (Fig. 1 right). Serology tests were per-
formed against herpes simplex virus and varicella zoster
virus. These tests showed negative results for immuno-
globulin (Ig) M and IgG. The possibility of human im-
munodeficiency virus was eliminated by a CD4 count of
750 cells/mm3. Different results were found in the
serology test for CMV. First, a serology test showed
negative results for IgM and IgG anti-CMV. A second
serology test showed a borderline positive result for IgG
anti-CMV with a titer of 0.9 U/mL. The last two
serology tests showed positive results for IgG anti-CMV
with titers of 5.0 U/mL and 3.8 U/mL. The four-fold
increase in IgG anti-CMV from 0.9 U/mL to 5.0 U/mL
within 8 days is an important finding (Table 2). Serial
images of his thorax and clinical pulmonary infection
score assessment accompanied by blood and sputum
Table 1 Inflammatory markers
Markers Day 1 Day 9 Day 39 Day 70 Day 85
White blood cells (/mm3) 15,800 9000 9500 18,900 7800
C-reactive protein (mg/L) 10 5 6 25 7
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cultures were regularly performed, and confirmed a
diagnosis of pneumonia in our patient. Based on his
medical history, physical examinations, laboratory re-
sults, and supporting examinations, the diagnosis of
CMV meningoencephalitis was made.
His clinical condition deteriorated even though ther-
apy with cefixime, acyclovir, dexamethasone, and pheny-
toin was administered intravenously. His cranial reflexes
started to become reduced after 1 week in our ICU. On
day 19, spontaneous respiration disappeared, cranial
reflexes became negative, and BSD was suspected be-
cause he had no response to all brain stem tests, in-
cluding an apnea test (Table 3). A vasopressor was
used to maintain his hemodynamic stability. His family
insisted life support should be continued indefinitely.
This condition lasted for almost 2 weeks with no im-
provement and brain stem tests were regularly per-
formed with negative results.
On day 30, he provided a vague response to painful
stimuli at his supraorbital nerve. On day 35, he opened
his eyes. Respiration started to appear on day 37,
followed by gradual movement of his fingers. His con-
sciousness improved from day 37, and he became fully
conscious on day 50. Ganciclovir replaced acyclovir
based on a four-fold increase of IgG anti-CMV serology
in a test result on day 27. Other therapies on days 19 to
30 included antibiotics based on culture, corticosteroids,
antibiotics, antipyretics, and antifungal agents. He also
had pleural effusion and a water-sealed device was in-
stalled on day 75. A higher positive end-expiratory pres-
sure (PEEP) on the ventilator was applied to maintain
oxygenation and prevent alveoli collapse. After day 80,
his respiration improved. On day 85, he was weaned
from the ventilator and was able to breathe without it.
He started to move his arms but his legs were still para-
lyzed. On day 90, he was moved from our ICU to in-
patient care where he stayed for 10 days until he went
home.
Discussion
CMV is a beta herpesvirus and can cause severe neuro-
logical syndromes. This virus is found worldwide. The
seroprevalence of CMV varies in different geographical
areas, ranging from 30 to 100 %. It usually attacks im-
munosuppressed patients. CMV encephalitis in acquired
immunodeficiency syndrome occurs in at least 6 % of
untreated patients with advanced human immunodefi-
ciency virus disease. CMV pneumonia occurred in 15 to
20 % of transplant recipients and patients with acquired
immunodeficiency syndrome, and is associated with a
mortality rate of 85 %. Most CMV infections resulted
from virus reactivation rather than primary infection.
CMV infection is usually asymptomatic in immunocom-
petent persons. Some studies have shown that CMV
infection occurs in critically sick patients who are admit-
ted to ICUs and the prevalence ranges from 0 to 35 %. It
can worsen the prognosis, prolong the ICU stay, ex-
tend ventilator use, and increase nosocomial infection
[1, 4, 5, 10, 11].
The diagnosis of meningoencephalitis in our patient at
the beginning of his illness was based on fever, headache,
a stiff neck, nausea, and vomitus as signs and symptoms
of meningitis. Encephalitis was suggested by altered
mental status, loss of consciousness, and cranial nerves
dysfunction. The viral etiology was strengthened by sup-
porting examinations and laboratory results [12, 13].
Fig. 1 CT scan showed the first result was normal (left) but the second showed a smeared bright area in ependymal cells at the lower area of the
third ventricle (right)
Table 2 Cytomegalovirus serology result
Cytomegalovirus Day 9 Day 19 Day 27 Day 39
Immunoglobulin M – – – –
Immunoglobulin G – + (0.9 U/mL) + (5.0 U/mL) + (3.8 U/mL)
Table 3 Brain stem death test results
Cranial nerves Day 21 Day 23 Day 25 Day 27 Day 30
II, III – – – – –
V, VII – – – – –
V, VII – – – – –
III, VI, VIII – Na Na – Na
IX, X – – – – –
X – – – – –
Apnea test – Na Na Na Na
Na not applied
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A tentative diagnosis of CMV meningoencephalitis
was made based on serology tests and CT scan result.
The first serology test in our patient on day 9 showed
negative results for IgM and IgG anti-CMV. A subse-
quent serology test on day 19 showed a borderline posi-
tive result for IgG anti-CMV. This was followed by a
positive result for IgG anti-CMV and a four-fold increase
in IgG anti-CMV on day 27. The second CT scan per-
formed on day 26 showed a smeared bright area in
ependymal cells at the lower area of his third ventricle.
The positive results of IgG anti-CMV and CT scan sup-
ported the diagnosis of CMV meningoencephalitis.
Recovery is needed to make a definite diagnosis.
CMV reactivation, but not primary infection, was sug-
gested in our patient based on serology method with a
positive result of IgG anti-CMV, a four-fold increase in
IgG anti-CMV, and a negative result for IgM anti-CMV.
The negative result for IgM anti-CMV may have been
due to unformed IgM or IgM that was produced but did
not reach a detectable level. The immunocompetent
status of our patient could also have affected the level of
IgM anti-CMV formed. The negative result for IgG anti-
CMV until day 19 is related to the time required for IgG
production, known as the infection window period. This
condition can occur in some viruses and is affected by
the immunological status of the patient and immuno-
suppressive drugs.
The subacute type of CMV infection in our patient,
called ventriculoencephalitis, was supported by severe
cranial nerve dysfunction, leading to BSD. All his cranial
reflexes disappeared on day 19. All brain stem tests,
including an apnea test that was performed on day 21,
showed no responses. These findings supported the sus-
pected condition of BSD. This condition was consistent
with the results of a CT scan and serology results on day
26 and day 27, respectively. A second complete BSD
examination could not be performed because the pa-
tient’s family refused a second apnea test. Therefore, the
diagnosis of BSD could not be made. Our patient was on
a ventilator and used a vasopressor with no improve-
ment for almost 2 weeks. However, his family refused
withdrawal of life support. During his illness, he was
administered antivirals, corticosteroids, antibiotics, anti-
pyretics, and antifungal medication [14].
There are no uniform guidelines available for diagnosis
of CMV infection in such critically ill, but immunocom-
petent, patients. An ideal diagnostic test should be able
to detect active CMV infection and differentiate it from
CMV disease. CMV infection is defined as isolation of
virus (viral culture), or detection of CMV proteins
(pp65) or nucleic acid by a polymerase chain reaction
from blood or other clinical samples. CMV disease is
confirmed by clinical findings suggestive of organ in-
volvement, as well as a demonstration of the virus by
viral isolation, histopathological testing, immunohisto-
chemical analysis, or in situ hybridization from the
relevant clinical sample obtained from the site of in-
volvement. Detection of CMV by polymerase chain reac-
tion alone is insufficient for confirming CMV disease.
Conventional methods for the diagnosis of CMV infec-
tion or disease are serology, including CMV-specific
antigen and antibody detection, which were used in our
patient, viral isolation by viral culture, and the molecular
method for detection of viral DNA from blood and other
clinical specimens [15–17].
Antiviral medication was changed from acyclovir to
ganciclovir on day 27 after the diagnosis of CMV menin-
goencephalitis was supported by a serologic result. All
brain tests, except for the apnea test, were performed on
the same day and showed negative results. An extraor-
dinary event occurred in our patient on day 30, after 4
days of ganciclovir treatment. We observed a vague re-
sponse to painful stimuli at his supraorbital nerve when
routine brain stem tests were performed. The response
became apparent and he opened his eyes on day 35.
However, respiration was still absent at this time and
started to appear as small respiratory efforts on day 37,
followed by motor activity at his fingers. He became
fully conscious on day 50. He started to breathe with-
out the ventilator on day 85 and moved out of our ICU
on day 90.
Ventilator-associated pneumonia and pleural effusion
act as complicating factors that worsen and prolong the
recovery process. Our patient was able to breathe on his
own with continuous positive airway pressure of 5
mmHg on day 66, but his respiration started to decrease
within the next week, accompanied by fever. His clinical
pulmonary infection score increased by more than 6.
Major pleural effusion was detected on day 75 and a
water-sealed device was applied on the same day. His
fever began to resolve after replacement of antibiotics on
day 69 and his respiration started to improve. Cultures
were regularly performed every 5 days and antibiotics
were used according to the result. Antifungal medication
was provided because our patient had a Candida score
of greater than 3 [18].
Study limitation
This case report has a few limitations. First, the diagno-
sis of BSD could not be made because our patient’s fam-
ily did not give permission for a second apnea test.
However, changes in result from a first to a second BSD
test are small. Therefore, even though a second BSD test
could not be performed, it was almost impossible that
our patient would regain brain stem function by the
time of a second test after the negative results of the first
BSD test [19]. Second, there is the limitation that sup-
portive and advance examinations were not performed
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because of financial reasons. Serology tests for IgM and
IgG anti-CMV could only be performed four times, a
CT scan two times, and EEG once. Magnetic resonance
imaging was not performed. Magnetic resonance im-
aging is superior to CT scans in evaluating central neural
system infections, including meningoencephalitis, but
this limitation can be overcome by a positive result in a
CT scan and serology test.
Conclusions
In conclusion, this case report shows an unusual recov-
ery process from CMV meningoencephalitis in an im-
munocompetent patient with BSD. Even though there
has been advancement in our understanding of the rela-
tionship between CMV infection with brain stem in-
volvement and immunocompetence in a patient, our
case is unusual. A diagnosis of BSD must be confirmed
with extreme caution, even if all BSD tests show nega-
tive results for a long time. CMV meningoencephalitis
should also be considered in the differential diagnosis in
immunocompetent patients whose cerebral spinal fluid
results show a suspected viral infection. Furthermore,
accurate therapy and simultaneous intensive care are im-
portant in a patient’s recovery process. The availability
of diagnostic testing also accelerates determination of
diagnosis, and this will affect treatment and prognosis.
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